课题基金 / 基金详情

PHASE I TRIAL OF MINOCYCLINE IN PATIENTS WITH CANCER

PHASE I TRIAL OF MINOCYCLINE IN PATIENTS WITH CANCER
米诺环素在癌症患者中的 I 期试验
批准号：
6117797
负责人：
Michael Gordon
金额：
$1.7万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6117797
关键词：
clinical research clinical trial phase I enzyme inhibitors human subject human therapy evaluation metalloendopeptidases metastasis neoplasm /cancer chemotherapy tetracyclines

项目摘要

项目成果

Michael Gordon的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The purpose of this research study is to determine the side effects of increasing doses of minocycline and to determine the maximum dose of minocycline that patients can tolerate. This study will also assess how long it takes for minocycline to leave the patients body. Minocycline is an antibiotic which is approved by the Food and Drug Administration for the treatment of certain infections. New research has revealed that it has the ability to inhibit the activity of certain enzymes in cancer cells which are important in allowing tumor cells to grow and spread. These results suggest that minocycline may help the patients body to stop or prevent the further growth of the patients cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE I TRIAL OF MINOCYCLINE IN PATIENTS WITH CANCER
PHASE I STUDY OF BB 10010 IN PATIENTS WITH RELASPED/REFRACTORY BREAST CANCER
STUDY OF THE SAFETY AND PHARMACOKINETIC PROFILES OF RECOMBINANT RHUMAB VEGF
STUDY OF THE SAFETY AND PHARMACOKINETIC PROFILES OF RECOMBINANT RHUMAB VEGF
海外基金